×
About 200 results

ALLMedicine™ Smith-Magenis Syndrome Center

Research & Reviews  76 results

Smith-Magenis Syndrome - GeneReviews® - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/n/gene/sms/

Mar 10th, 2022 - Smith-Magenis syndrome (SMS) is characterized by distinctive physical features (particularly coarse facial features that progress with age), developmental delay, cognitive impairment, behavioral abnormalities, sleep disturbance, and childhood-onse...

Children with neurodevelopmental disorders: how do they sleep?
https://doi.org/10.1097/YCO.0000000000000790
Current Opinion in Psychiatry; Belli A, Breda M et. al.

Feb 16th, 2022 - In this review we summarized the available evidence on sleep disorders in children with neurodevelopmental disorders (NDDs) in particular: intellectual disability (including some genetic conditions such as Prader-Willi Syndrome, Smith-Magenis Synd...

Caregivers' experience of sleep management in Smith-Magenis syndrome: a mixed-methods s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815225
Orphanet Journal of Rare Diseases; Agar G, Bissell S et. al.

Feb 6th, 2022 - Smith-Magenis syndrome (SMS) is a rare genetic syndrome associated with a unique profile of early morning waking and daytime sleepiness. Children with SMS evidence high rates of self-injury and aggression and have a preference for adult over peer ...

Methylphenidate for attention-deficit/hyperactivity disorder in patients with Smith-Mag...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424817
Orphanet Journal of Rare Diseases; Müller AR, Zinkstok JR et. al.

Sep 10th, 2021 - Smith-Magenis syndrome (SMS) is a rare genetic neurodevelopmental disorder characterized by intellectual disability and severe behavioural and sleep disturbances. Often, patients with SMS are diagnosed with attention-deficit/hyperactivity disorder...

Copy number variations of chromosome 17p11.2 region in children with development delay ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411507
BMC Medical Genomics; Zhang Y, Liu X et. al.

Sep 3rd, 2021 - Deletion and duplication of the 3.7 Mb region in 17p11.2 result in two syndromes, Smith-Magenis syndrome and Potocki-Lupski syndrome, which are well-known development disorders. The purpose of this study was to determine the prevalence, genetic ch...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  2 results

Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS
https://clinicaltrials.gov/ct2/show/NCT02231008

May 16th, 2016 - The aim of this study is to investigate tasimelteon vs. placebo on sleep disturbances of individuals with Smith-Magenis Syndrome.

Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances
https://clinicaltrials.gov/ct2/show/NCT01903681

Apr 4th, 2014 - There is increasing evidence that chronic sleep disorders in children with autism spectrum disorder (ASD), Angelman Syndrome (AS) and Smith-Magenis syndrome (SMS) are associated with disturbed melatonin secretion and melatonin administration has b...

see more →

News  1 results

EMA Handed Down Fewer Positive Drug Opinions in 2018
https://www.medscape.com/viewarticle/907402

Jan 9th, 2019 - In 2018, the European Medicines Agency (EMA) recommended marketing authorization for 84 new medicines, down from 92 in 2017. The 84 medicines given a thumbs up by EMA's Committee for Medicinal Products for Human Use include 42 agents with a new ac...

see more →